ASSESSMENT OF EFFECTIVENESS OF FLUDARABINE-CONTAINING CHEMOTHERAPY PROGRAMS IN ONCOHEMATOLOGICAL PATIENTS
https://doi.org/10.51523/2708-6011.2014-11-2-11
Abstract
Purpose: to assess effectiveness of fludarabine-containing chemotherapy programs in treatment of oncohematological patients after relapse or in primary chemoresistance. Material and methods. Within 2006-2013, 11 patients with various oncohematologic disorders were treated using fludarabine-containing high-dose chemotherapy programs FLAG or FLAG-Ida at the Republican Research Center for Radiation Medicine and Human Ecology. Results. The best results of this pilot study were obtained in the chemotherapy program FLAG-Ida. Remission was achieved in younger patients, in contrast to the group of elderly patients with no remission. All the patients who achieved remission were female, and among the 7 patients, who did not achieve remission, more than half were men. Conclusion. Thus, on the whole the fludarabine-containing programs of chemotherapy are effective in the treatment for oncohematological pathology, but further research is needed to develop a more differentiated approach to the application of the programs to improve the effectiveness of the therapy of these diseases.
Keywords
онкогематология,
флударабин,
FLAG,
рецидив,
химиорезистентность,
oncohematology,
fludarabine,
FLAG,
relapse,
chemoresistance
About the Authors
D. V. Kravchenko
Republican Research Center for Radiation Medicine and Human Ecology, Gomel
Belarus
Belarus
D. K. Novik
Republican Research Center for Radiation Medicine and Human Ecology, Gomel
Belarus
Belarus
References
1. Fludarabine potentiates metabolism of cytarabine in patients with acute myelogenous leukemia during therapy / V. Gandhi [et al.] // J.Clin.Oncol. - 1993. - Vol. 11. - P. 116-124.
2. Применение флударабинсодержащих протоколов химиотерапии в лечении больных с резистентными формами острой миелобластной лейкемии. Материалы конференции «Терапия сопровождения в терапии онкологичных больных» / Н. Н. Третяк [и др.] // Онкология. - 2007. - № 3. - С. 274-277.
3. Grant, S. Ara-C: cellular and molecular pharmacology / S. Grant // Adv. Cancer Res. - 1998. - Vol. 72. - P. 133-197.
4. FLAG-IDA in the treatment of refractory/relapsed acute myeloid leukemia: single center experience / D. Pastore [et al.] // Ann. Hematol. - 2003. - Vol. 82. - P. 231-235.
5. FLAG for refractory and relapse acute myeloid leukemia / I. M. Huhmann [et al.] // Ann. Hematol. - 1996. - Vol. 73. - P. 265-271.
6. Plunkett, W. Metabolism and action of fludarabine phosphate / W. Plunkett, P. Huang, V. Gandhi. // Semin. Oncology - 1990. - Vol. 17. - P. 3-17.
7. Gandhi, V. Cellular and clinical pharmacology of fludarabine / V. Gandhi, W. Plunkett. // Clin. Pharmacokinet. - 2002. - Vol. 41. - P. 93-103.
8. Effect of fludarabine and arabinosylcytosine on multidrugre-sistance cells / A. Michelutti [et al.] // Haematologica. - 1997. - Vol. 82. - P. 143-147.
9. Fludarabine, cytarabine, and G-CSF (FLAG) for the treatment of poor risk acutemyeloid leukemia / M. Montillo [et al.] // Am. J. Hematology. - 1998. - Vol. 5. - P. 105-109.
10. Treatment of chronic myeloid leukemia in the blastic phase with fludarabine, cytosine arabinoside and G-CSF (FLAG). / A. Tedeschi [et al.] // Eur. J.Haematology. - 2000. - Vol. 64. - P. 182-187.
11. IDA-FLAG regimen for the therapy of primary refractory and relapse acute leukemia: a single-center experience / D. Pastore, G. Specchia, P. Carluccio [et al.] // Ann. Hematology. - 2003. - Vol. 82. - P. 231-235.
12. First line therapy with fludarabine combinations in 42 patients with eiter myelodysplastic syndrome or therapy related acute myeloid leukemia. / M. Clavio [et al.] // Leukemia Lymphoma. - 2001. - Vol. 40. - P. 305-313.
13. Fludarabine and cytarabine as continuous seguential infusion for elderly patients with acute myeloid leukemia / F. Ferrara [et al.] // Blood. - 2002. - Vol. 100. - P. 1335-1344.
Review
For citations:
Kravchenko D.V., Novik D.K. ASSESSMENT OF EFFECTIVENESS OF FLUDARABINE-CONTAINING CHEMOTHERAPY PROGRAMS IN ONCOHEMATOLOGICAL PATIENTS. Health and Ecology Issues. 2014;(2):53-56. (In Russ.) https://doi.org/10.51523/2708-6011.2014-11-2-11
Views: 281
Email this article 